The potent psychoactive properties of the cannabinoids and the identification and cloning of a cannabinoid receptor suggest they mimic endogenous compounds which modulate neural signals for mood, memory, movement and pain. Preliminary studies (below) have found that cannabinoids, potently and reversibly, inhibit N-type calcium channels via a Pertussis toxin-sensitive mechanism. The first part of the proposed study will extend these observations to acutely dissociated CNS neurons from regions rich in cannabinoid receptor with the aim to fully dissect the signal transduction pathway between the receptor and calcium channel. The second part proposes to develop polyclonal antibodies against the cannabinoid receptor using synthetic peptides based on the cDNA sequence of the cloned receptor. These antibodies will be used for anatomical, developmental, and biochemical characterization of the receptor. We anticipate that by utilizing two complementary techniques, one electrophysiological and the other immunological, we will substantially add to our knowledge of the cellular actions of the cannabinoids. This insight will be useful as it will both increase our understanding of a novel neurotransmitter system with marked behavioral effects, and will also allow a more rational assessment of the use of cannabinoids as therapeutic agents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Clinical Investigator Award (CIA) (K08)
Project #
1K08NS001588-01
Application #
3084750
Study Section
NST-2 Subcommittee (NST)
Project Start
1992-07-01
Project End
1996-06-30
Budget Start
1992-07-01
Budget End
1993-06-30
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Garcia, D E; Brown, S; Hille, B et al. (1998) Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor. J Neurosci 18:2834-41
Felder, C C; Joyce, K E; Briley, E M et al. (1998) LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 284:291-7
Garcia, D E; Li, B; Garcia-Ferreiro, R E et al. (1998) G-protein beta-subunit specificity in the fast membrane-delimited inhibition of Ca2+ channels. J Neurosci 18:9163-70
Felder, C C; Joyce, K E; Briley, E M et al. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-50
Priller, J; Briley, E M; Mansouri, J et al. (1995) Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors. Mol Pharmacol 48:288-92
Mackie, K; Lai, Y; Westenbroek, R et al. (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15:6552-61
Felder, C C; Briley, E M; Axelrod, J et al. (1993) Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci U S A 90:7656-60
Mackie, K; Devane, W A; Hille, B (1993) Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol 44:498-503